

place the summary report and each grant recipient's final report with the National Technical Information Service (NTIS) to further the agency's efforts to make the information more available and accessible to the public.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

#### *Additional Requirements*

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I of the program announcement, as posted on the CDC Web site.

- AR-1 Human Subjects Requirements.
- AR-2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research.
- AR-9 Paperwork Reduction Act Requirements.
- AR-10 Smoke-Free Workplace Requirement.
- AR-11 Healthy People 2010.
- AR-12 Lobbying Restrictions.
- AR-13 Prohibition on Use of CDC Funds for Certain Gun Control Activities.
- AR-20 Conference Support.

Executive Order 12372 does not apply to this program.

#### **J. Where To Obtain Additional Information**

This and other CDC announcements, the necessary applications, and associated forms can be found on the CDC Web site, Internet address: <http://www.cdc.gov>.

Click on "Funding" then "Grants and Cooperative Agreements."

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Rd., Atlanta, GA 30341-4146, Telephone: (770) 488-2700.

For business management and budget assistance, contact: Nancy Pillar, Grants Management Specialist, Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, Telephone: (770) 488-2721, E-mail address: [NPillar@cdc.gov](mailto:NPillar@cdc.gov).

For program technical assistance, contact: Candice Jackson, Project Officer, Division of Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS K60, Atlanta, GA 30341-3724, Telephone: (770) 488-1571, E-mail address: [CJackson@cdc.gov](mailto:CJackson@cdc.gov).

Dated: February 13, 2003.

**Sandra R. Manning,**

*CGFM Director, Procurement and Grants Office, Centers for Disease Control and Prevention.*

[FR Doc. 03-4061 Filed 2-20-03; 8:45 am]

**BILLING CODE 4163-18-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

#### **Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Clinical Laboratory Improvement Advisory Committee (CLIAC).

*Times and Dates:* 8:30 a.m.-5 p.m., March 12, 2003.

8:30 a.m.-3:30 p.m., March 13, 2003.

*Place:* Sheraton Colony Square Hotel, 188 14th Street NE, Atlanta, Georgia 30361.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

*Purpose:* This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

*Matters to Be Discussed:* The agenda will include updates from CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration; a report on the recently published CLIA Quality Systems final rule; a report on rapid HIV testing; a demonstration of CytoView™; and various perspectives and discussion on direct access testing. Agenda items are subject to change as priorities dictate.

*Providing Oral or Written Comments:* It is the policy of the CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. *Oral Comments:* In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated).

Speakers must also submit their comments in writing for inclusion in the meeting's Summary Report. *Written Comments:* For individuals or groups unable to attend the meeting, the CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the committee for their consideration and public distribution. Written comments, one hard copy with original signature, should be provided to the contact person below. Written comments will be included in the meeting's Summary Report.

*Contact Person for Additional Information:* Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop F-11, Atlanta, Georgia 30341-3717; telephone (770)488-8042; fax (770)488-8279; or via e-mail at [RWhalen@cdc.gov](mailto:RWhalen@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 13, 2003.

**Joseph E. Salter,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 03-4059 Filed 2-20-03; 8:45 am]

**BILLING CODE 4163-18-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Centers for Disease Control and Prevention**

#### **National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect: Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meeting.

*Name:* National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE).

*Times and Dates:* 8:30 a.m.-4 p.m., March 13, 2003. 8:30 a.m.-11:45 a.m., March 14, 2003.

*Place:* Doubletree Hotel Atlanta/Buckhead, 3342 Peachtree Road, NE.,

Atlanta, Georgia 30326, telephone 404/231-1234, fax 404/231-3112.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

*Purpose:* The Secretary is authorized by the Public Health Service Act, Section 399G, (42 U.S.C. Section 280f, as added by Public Law 105-392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to:

(1) Foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

*Matters to Be Discussed:* Agenda items include: an update from the National Center on Birth Defects and Developmental Disabilities Scientific Working Group on Diagnostic Guidelines for FAS and Alcohol-Related Neurodevelopmental Disabilities (ARND); an update on activities from the Interagency Coordinating Committee on Fetal Alcohol Syndrome; new research and program updates from the CDC and other Federal agencies; and working group updates. Additional agenda items include: task force discussions on the use of the term fetal alcohol spectrum disorders: What is it? When is it appropriate to use it?; provider education and FAS prevention; development of a clear message for pediatricians, nurses, and other providers: how the FAS diagnosis will benefit the child and family; future topics, and scheduling the next meeting.

Agenda items are subject to change as priorities dictate.

**CONTACT PERSON FOR MORE INFORMATION:** R. Louise Floyd, DSN, RN, Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 4700 Buford Highway, NE, (F-49), Atlanta, Georgia 30333, telephone 770/488-7372, fax 770/488-7361.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: February 13, 2003.

**Joseph E. Salter,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 03-4060 Filed 2-20-03; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH).

*Times and Dates:* 8 p.m.-10 p.m., March 5, 2003. 8 a.m.-5:30 p.m., March 6, 2003. 8 a.m.-5 p.m., March 7, 2003.

*Place:* Little America Hotel, 500 South Main Street, Salt Lake City, Utah 84411, telephone (801) 363-6787.

*Status:* Open 8 p.m.-10 p.m., March 5, 2003. Open 8 a.m.-9 a.m., March 6, 2003. Closed 9 a.m.-5:30 p.m., March 6, 2003. Closed 8 a.m.-5 p.m., March 7, 2003.

*Purpose:* The Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) received in response to the Institute's standard grants review and funding cycles pertaining to research issues in occupational safety and health, and allied areas. It is the intent of the NIOSH to support broad-based research endeavors in keeping with the Institute's program goals. This will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses, as well as to support more focused research projects, which will lead to improvements in the delivery of occupational safety and health services and the prevention of work-related injury and illness. It is anticipated that research funded will promote these program goals.

*Matters To Be Discussed:* The meeting will convene in open session from 8-10 p.m. on March 5, 2003 and 8-9 a.m. on March 6, 2003, to address matters related to the conduct of Study Section business. The remainder of the meeting will proceed in closed session. The purpose of the closed sessions is for the SOHSS to consider safety and occupational health-related grant applications. These portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6) title 5 U.S.C., and the determination of the Director, Management Analysis and

Services Office, Centers for Disease Control and Prevention, pursuant to Pub. L. 92-463.

As provided under 41 CFR 102-3.150(b), the public health urgency of this agency business requires that the meeting be held prior to the first available date for publication of this notice in the **Federal Register**.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Michael Galvin, Ph.D., NIOSH Health Scientist, 1600 Clifton Road, NE., Mailstop E-20, Atlanta, Georgia 30333, telephone (404) 498-2524, fax (404) 498-2569.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 13, 2003.

**Joseph E. Salter,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 03-4058 Filed 2-20-03; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Board on Radiation and Worker Health: Meeting.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Advisory Board on Radiation and Worker Health (ABRWH), National Institute for Occupational Safety and Health (NIOSH).

*Time and Date:* 8 a.m.-5 p.m., March 7, 2003.

*Place:* The Westin Cincinnati, 21 East Fifth Street, Cincinnati, Ohio 45202, telephone (513) 621-7700, fax (513) 852-5670.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

*Background:* The Advisory Board on Radiation and Worker Health ("the Board") was established under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA) of 2000 to advise the President, through the Secretary of Health and Human Services (HHS), on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Board include providing advice on the development of probability of causation guidelines which have been promulgated by HHS as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, evaluation of the scientific validity and